AmbioPharm: difference between revisions

Diff·revision 8 → 9·08:45, 6 Nov 2025

Difference between revision 8 and revision 9 of AmbioPharm. 10 lines changed; the page grew by 739 bytes.

Revision 8 — 00:25, 1 Nov 2025 GMP_Gita (talk) rm a duplicated category 6,078 bytes +1,561	Revision 9 — 08:45, 6 Nov 2025 GHK_Gwendolen (talk) add the transit window each regional warehouse serves 6,817 bytes +739
1	{{Infobox organisation	1	{{Infobox organisation
2	\| name = AmbioPharm, Inc.	2	\| name = AmbioPharm, Inc.
+		3	\| image = facility.svg
+		4	\| caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
3	\| Legal name = AmbioPharm, Inc.	5	\| Legal name = AmbioPharm, Inc.
4	\| Trading name = AMB	6	\| Trading name = AMB
⋮		⋮
31		33
32	Two determinations distinguish the submitted set from most entities covered here. Water content by [[Karl Fischer titration\|Karl Fischer titration]] appears on the certificates described, and the [[Counter-ion\|counter-ion]] is reported as a figure with its unit rather than named or omitted.{{r\|reports,usp1503}} Together with [[Peptide content\|peptide content]] on a separate line from chromatographic purity, those are what let a purity percentage be read as a statement about mass. Their routine presence is the most useful documentary observation available about this organisation. Reports also describe the release as signed and dated by a named individual rather than initialled.{{r\|reports}}	34	Two determinations distinguish the submitted set from most entities covered here. Water content by [[Karl Fischer titration\|Karl Fischer titration]] appears on the certificates described, and the [[Counter-ion\|counter-ion]] is reported as a figure with its unit rather than named or omitted.{{r\|reports,usp1503}} Together with [[Peptide content\|peptide content]] on a separate line from chromatographic purity, those are what let a purity percentage be read as a statement about mass. Their routine presence is the most useful documentary observation available about this organisation. Reports also describe the release as signed and dated by a named individual rather than initialled.{{r\|reports}}
+		35
+		36	== Product range ==
+		37	\| Class \| Representative listings \| Documentation reported \|
+		38	\|---\|---\|---\|
+		39	\| Peptide active ingredients \| Bulk peptide actives, protected fragments \| Specification sheet with purity, water, content and counter-ion \|
+		40	\| Incretin analogues \| Semaglutide, tirzepatide, retatrutide \| Batch certificate with HPLC trace and mass confirmation \|
+		41	\| Research peptides \| BPC-157, TB-500, growth-hormone secretagogues \| Certificate with purity, appearance, water and counter-ion \|
+		42	\| Raw materials \| Bulk powders \| Certificate with purity; specification sheet on request \|
33		43
34	== References ==	44	== References ==